Anthony Butler

Anthony Butler

Auto-generated profile, based on publicly available information

Anthony Butler

MARS Bioimaging Ltd, Christchurch, New Zealand

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Nanoscale Horizons
Verified
Journal Article
Closed access
PDF file
FOFatemeh Ostadhossein
Fatemeh Ostadhossein
PMParikshit Moitra
Parikshit Moitra
NGNivetha Gunaseelan
Nivetha Gunaseelan
MNMichael Nelappana
Michael Nelappana
CLChiara Lowe
Chiara Lowe
DPDipanjan Pan
Dipanjan Pan
Gastrointestinal (GI) tract is one of the hard-to-reach target tissues for the delivery of contrast agents and drugs mediated by nanoparticles due to its harsh environment. Herein, we overcame this barrier by designing orally ingestible probiotic vectors for ‘hitchhiking’ ultrasmall hafnia (HfO2) (∼1–2 nm) nanoparticles. The minute-made synthesis of these nanoparticles is accomplished through a simple reduction reaction. These nanoparticles were incubated with probiotic bacteria with potential health benefits and were non-specifically taken up due to their small size. Subsequently, the bacteria were lyophilized and packed into a capsule to be administered orally as the radiopaque contrast agents for delineating the GI features. These nano-bio-hybrid entities could successfully be utilized as contrast agents in vivo in the conventional and multispectral computed tomography (CT). We demonstrated in ‘color’ the accumulated nanoparticles using advanced detectors of the photon counting CT. The enhanced nano-bio-interfacing capability achieved here can circumvent traditional nanoparticle solubility and delivery problems while offering a patient friendly approach for GI imaging to replace the currently practiced barium meal.

18 December 2018 in Contrast Media & Molecular Imaging
Verified
Journal Article
Open access
PDF file
MMMahdieh Moghiseh
Mahdieh Moghiseh
CLChiara Lowe
Chiara Lowe
JLJohn G. Lewis
John G. Lewis
Dhiraj KumarDhiraj Kumar
Dhiraj Kumar
ABAnthony Butler
Anthony Butler
ARAamir Younis Raja
Aamir Younis Raja
The purpose of the present study was to demonstrate anin vitroproof of principle that spectral photon-counting CT can measure gold-labelled specific antibodies targeted to specific cancer cells. A crossover study was performed with Raji lymphoma cancer cells and HER2-positive SKBR3 breast cancer cells using a MARS spectral CT scanner. Raji cells were incubated with monoclonal antibody-labelled gold, rituximab (specific antibody to Raji cells), and trastuzumab (as a control); HER2-positive SKBR3 breast cancer cells were incubated with monoclonal antibody-labelled gold, trastuzumab (specific antibody to HER2-positive cancer cells), and rituximab (as a control). The calibration vials with multiple concentrations of nonfunctionalised gold nanoparticles were used to calibrate spectral CT. Spectral imaging results showed that the Raji cells-rituximab-gold and HER2-positive cells-trastuzumab-gold had a quantifiable amount of gold, 5.97 mg and 0.78 mg, respectively. In contrast, both cell lines incubated with control antibody-labelled gold nanoparticles had less gold attached (1.22 mg and 0.15 mg, respectively). These results demonstrate the proof of principle that spectral molecular CT imaging can identify and quantify specific monoclonal antibody-labelled gold nanoparticles taken up by Raji cells and HER2-positive SKBR3 breast cancer cells. The present study reports the future potential of spectral molecular imaging in detecting tumour heterogeneity so that treatment can be tuned accordingly, leading to more effective personalised medicine.

29 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MMMahdieh Moghiseh
Mahdieh Moghiseh
ESEmily Searle
Emily Searle
DDDevyani Dixit
Devyani Dixit
JKJohoon Kim
Johoon Kim
YDYuxi C. Dong
Yuxi C. Dong
MLMars Bioimaging Ltd.
Mars Bioimaging Ltd.
A key process in the development of atherosclerotic plaques is the recruitment of monocytes into the artery wall. Using spectral photon-counting computed tomography we examine whether monocyte deposition within the artery wall of ApoE-/- mouse can be detected. Primary mouse monocytes were labelled by incubating them with 15 nm gold nanoparticles coated with 11-mercaptoundecanoic acid The monocyte uptake of the particle was confirmed by electron microscopy of the cells before injection into 6-week-old apolipoprotein E deficient (ApoE-/-) mouse that had been fed with the Western diet for 10 weeks. Four days following injection, the mouse was sacrificed and imaged using a MARS spectral photon counting computed tomography scanner with a spectral range of 7 to 120 KeV with five energy bins. Imaging analysis showed the presence of X-ray dense material within the mouse aortic arch which was consistent with the spectral characteristic of gold rather than calcium. The imaging is interpreted as showing the deposition of gold nanoparticles containing monocytes within the mouse aorta. The results of our study determined that spectral photon-counting computed tomography could provide quantitative information about gold nanoparticles labelled monocytes in voxels of 90 × 90 × 90 µm3. The imaging was consistent with previous micro-CT and electron microscopy of mice using the same nanoparticles. This study demonstrates that spectral photon-counting computed tomography, using a MARS small bore scanner, can detect a fundamental atherogenic process within mouse models of atherogenesis. The present study demonstrates the feasibility of spectral photon-counting computed tomography as an emerging molecular imaging modality to detect atherosclerotic disease.

31 January 2023 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
Dhiraj KumarDhiraj Kumar
Dhiraj Kumar
MMMahdieh Moghiseh
Mahdieh Moghiseh
KCKenny Chitcholtan
Kenny Chitcholtan
Isha MutrejaIsha Mutreja
Isha Mutreja
CLChiara Lowe
Chiara Lowe
ARAamir Younis Raja
Aamir Younis Raja
Emerging multifunctional nanoparticulate formulations take advantage of nano-meter scale size and surface chemistry to work as a therapeutic delivery agent and a diagnostic tool for non-invasive real-time monitoring using imaging technologies. Here, we evaluate the selective uptake of 18 nm and 80 nm sized gold nanoparticles (AuNPs) by SKOV3 (4 times higher) ovarian cancer (OC) cells (compared to OVCAR5) in vitro, quantified by inductively coupled plasma (ICP) and MARS spectral photon-counting CT imaging (MARS SPCCT). Based on in vitro analysis, pristine AuNPs (18 nm) and surface modified AuNPs (18 nm) were chosen as a contrast agent for MARS SPCCT. The chemical analysis by FTIR spectroscopy confirmed the luteinizing hormone-releasing hormone (LHRH) conjugation to the AuNPs surface. For the first time, LHRH conjugated AuNPs were used for in vitro and selective in vivo OC targeting. The ICP-MS analysis confirmed preferential uptake of LHRH modified AuNPs by organs residing in the abdominal cavity with OC nodules (pancreas: 0.46 ng mg−1, mesentery: 0.89 ng mg−1, ovary: 1.43 ng mg−1, and abdominal wall: 2.12 ng mg−1) whereas the MARS SPCCT analysis suggested scattered accumulation of metal around the abdominal cavity. Therefore, the study showed the exciting potential of LHRH conjugated AuNPs to target ovarian cancer and also as a potential contrast agent for novel SPCCT imaging technology.

1 April 2021 in APL Bioengineering
Verified
Journal Article
Open access
PDF file
KBKenzie Baer
Kenzie Baer
SKSandra Kieser
Sandra Kieser
BSBen Schon
Ben Schon
KRKishore Rajendran
Kishore Rajendran
THTimen Ten Harkel
Timen Ten Harkel
TWTim Woodfield
Tim Woodfield
Detection of early osteoarthritis to stabilize or reverse the damage to articular cartilage would improve patient function, reduce disability, and limit the need for joint replacement. In this study, we investigated nondestructive photon-processing spectral computed tomography (CT) for the quantitative measurement of the glycosaminoglycan (GAG) content compared to destructive histological and biochemical assay techniques in normal and osteoarthritic tissues. Cartilage-bone cores from healthy bovine stifles were incubated in 50% ioxaglate (Hexabrix®) or 100% gadobenate dimeglumine (MultiHance®). A photon-processing spectral CT (MARS) scanner with a CdTe-Medipix3RX detector imaged samples. Calibration phantoms of ioxaglate and gadobenate dimeglumine were used to determine iodine and gadolinium concentrations from photon-processing spectral CT images to correlate with the GAG content measured using a dimethylmethylene blue assay. The zonal distribution of GAG was compared between photon-processing spectral CT images and histological sections. Furthermore, discrimination and quantification of GAG in osteoarthritic human tibial plateau tissue using the same contrast agents were demonstrated. Contrast agent concentrations were inversely related to the GAG content. The GAG concentration increased from 25 μg/ml (85 mg/ml iodine or 43 mg/ml gadolinium) in the superficial layer to 75 μg/ml (65 mg/ml iodine or 37 mg/ml gadolinium) in the deep layer of healthy bovine cartilage. Deep zone articular cartilage could be distinguished from subchondral bone by utilizing the material decomposition technique. Photon-processing spectral CT images correlated with histological sections in healthy and osteoarthritic tissues. Post-imaging material decomposition was able to quantify the GAG content and distribution throughout healthy and osteoarthritic cartilage using Hexabrix® and MultiHance® while differentiating the underlying subchondral bone.

18 June 2020 in IEEE Transactions on Radiation and Plasma Medical Sciences
Verified
Journal Article
Closed access
EMEmmanuel Marfo
Emmanuel Marfo
NANigel G. Anderson
Nigel G. Anderson
ABAnthony P. H. Butler
Anthony P. H. Butler
NSNanette Schleich
Nanette Schleich
PCPierre Carbonez
Pierre Carbonez
ARAamir Younis Raja
Aamir Younis Raja
Photon-counting CT offers the potential to provide new diagnostic information. In this study, we sought to determine the interplay between material identification errors, image quality indicators, and radiation doses using photon-counting spectral CT, and to determine whether this relationship is replicated in spectral CT scans of mice. Custom-built Perspex phantoms were used to measure signal-to-noise ratio and spatial resolution, and to measure radiation dose using thermoluminescent dosimeters. A multi-contrast calibration phantom containing inserts with different concentrations of gadolinium (1, 2, 4 and 8 mg/mL), hydroxyapatite rods (0, 54.3, 104.3, 211.7, 402.3 and 808.5 mg/mL) along with water and lipid was used to assess material identification errors. Image acquisition was performed using the MARS photon-counting scanner with four energy channels (30-45, 45-60, 60-78 and 78-118 keV) at four different tube currents (24, 34, 44 and 55 mA). As increased tube current showed no significant effect on material characterisation, small animal dosimetry was performed with 24 mA tube current using two non-contrast mice and one mouse injected with gadolinium. Results demonstrated that a tube current increase from 24 to 54 mA improved the signal-to-noise ratio and spatial resolution by <10%, gadolinium identification by 160%. Imaging results of the mice showed no obvious artefacts, and the mean absorbed dose measured for the three mice was 27.3±2.4 mGy. The results suggest that the energy resolving capability of photon-counting CT maintains diagnostically relevant image quality with high levels of material discrimination at reduced radiation dose.